| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 10,000 | $6.11 | $61,100.00 | -15.5% | +32.9% | +13.8% | |
| Jun 4, 2024 | ANIP Ani Pharmaceuticals Inc | Carey Stephen P.55 | SVP &CFO | Sell | 5,000 | $63.58 | $317,900.00 | -3.0% | -2.7% | -6.0% | |
| Jun 4, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $275.01 | $1,980,099.84 | -34.5% | +29.0% | +18.6% | |
| Jun 3, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 192,794 | $829.77 | $159,974,049.59 | - | +15.1% | -9.7% | |
| Jun 3, 2024 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 750 | $819.47 | $614,602.50 | -9.5% | +15.1% | -9.7% | |
| Jun 3, 2024 | COLL Collegium Pharmaceutical, Inc | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 25,000 | $32.57 | $814,180.12 | -8.2% | +16.0% | -9.4% | |
| Jun 3, 2024 | EOLS Evolus, Inc. | Malik Vikram54 | Director | Sell | 7,500 | $12.96 | $97,203.00 | -3.0% | +19.8% | -23.4% | |
| Jun 3, 2024 | LLY Eli Lilly & Co | Norton Johna | EVP, Global Quality | Sell | 7,056 | $819.38 | $5,781,545.28 | -21.7% | +15.1% | -9.7% | |
| Jun 3, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $42.65 | $21,325.90 | -0.6% | +11.2% | -38.4% | |
| Jun 3, 2024 | ANIP Ani Pharmaceuticals Inc | Gassert Chad60 | SVP - Corp. Dev. &Strategy | Sell | 20,000 | $64.41 | $1,288,200.00 | -8.6% | -0.6% | -2.8% | |
| Jun 3, 2024 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 710 | $14.55 | $10,330.50 | -0.1% | -37.2% | +14.0% | |
| Jun 3, 2024 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 1,094 | $14.55 | $15,917.70 | -0.3% | -37.2% | +14.0% | |
| Jun 3, 2024 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 455 | $14.55 | $6,620.25 | -0.4% | -37.2% | +14.0% | |
| Jun 3, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 521,380 | $19.79 | $10,319,439.38 | -32.0% | -29.2% | +167.1% | |
| Jun 3, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 546 | $14.55 | $7,944.30 | -0.4% | -37.2% | +14.0% | |
| May 31, 2024 | DVAX Dynavax Technologies Corp | Cano Francis | Director | Sell | 3,615 | $11.93 | $43,126.95 | -8.9% | -6.1% | -18.3% | |
| May 31, 2024 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | President | Sell | 1,179 | $80.82 | $95,286.78 | -1.1% | +28.1% | -7.7% | |
| May 31, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 22,206 | $822.11 | $18,255,870.84 | - | +14.6% | -10.1% | |
| May 31, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 273 | $136.55 | $37,278.15 | -3.5% | -5.2% | -9.1% | |
| May 31, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $271.29 | $1,953,289.46 | -29.4% | +30.9% | +15.9% | |
| May 30, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 129,667 | $20.55 | $2,665,244.15 | -28.3% | -28.1% | +177.7% | |
| May 30, 2024 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel55 | See Remarks | Sell | 12,873 | $79.86 | $1,028,037.78 | -13.8% | +36.3% | -6.2% | |
| May 30, 2024 | BCRX Biocryst Pharmaceuticals Inc | Levin Alan G | Director | Buy | 7,861 | $6.36 | $49,995.96 | +21.2% | +30.1% | +63.6% | |
| May 29, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 130,385 | $811.04 | $105,747,974.80 | - | +17.6% | -11.0% | |
| May 29, 2024 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,830 | $4.61 | $8,436.30 | -2.8% | +100.0% | +39.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.